Study, (Author/year/Country) | Cancer traits | Treatment | Patients | Age, | Follow-up, months (Range) | Therapy Response/Survival Data | NOS Score | |
---|---|---|---|---|---|---|---|---|
Miao/2016/China [10] | EOC; Serous papillary histology (n = 216, 62.8%); FIGO stage III (n = 168, 48.8%); platinum-resistant group (n = 96, 27.9%); | Comprehensive surgical staging or tumor debulking followed by 6 cycles of adjuvant chemotherapy. | 344 | 55 (45–84) | 72 (61-97) | PFS (HR) PLR (cut-off value: 207) Ua: 3.851 (2.958 to 5.014) Ma: 1.952 (1.430 to 2.662) NLR (cut-off value: 3.02) Ua: 5.093 (3.886 to 6.676) Ma: 1.733 (1.225 to 2.453) | OS (HR) PLR (cut-off value: 207) Ua: 3.863 (2.960 to 5.043) Ma: 2.167 (1.565 to 3.000) NLR (cut-off value: 3.02) Ua: 4.970 (3.794 to 6.511) Ma: 1.616 (1.138 to 2.297) | 9 |
Wang/2015/China [12] | SOC; FIGO stage III-IV (n = 93, 73.8%) | Cytoreductive surgery including para-aortic and pelvic lymph node dissection followed by platinum-based chemotherapy. | 126 | NA | 41.3 (3.3–70.4) | PFS (HR) PLR (cut-off value: 187.6) Ua: 1.306 (0.684–2.495) Ma: 1.127 (0.433–2.932) NLR (cut-off value: 2.65) Ua: 3.191 (1.514–6.728) Ma: 3.554 (1.389–9.096) | OS (HR) PLR (cut-off value: 187.6) Ua: 1.090 (0.510–2.329) Ma: 1.689 (0.590–4.835) NLR (cut-off value: 2.65) Ua: 3.775 (1.497–9.519) Ma: 5.302 (1.817–15.471 | 8 |
Cho/2009/Korea [13] | EOC; Serous papillary histology (n = 131, 68.2%); FIGO stage III-IV (n = 125, 65.1%) | Treatment according to NCCN guidelines. | 192 | 51.8 ± 12.9 | 20.9 | DFS P = 0.014 | OS (HR) NLR (cut-off value: 2.6) Ua: 6.05 (1.77–20.71) Ma: 8.42 (1.09–64.84) | 8 |
Wang/2016/China [14] | OC; EOC (N = 122 85.3%); FIGO stage III-IV (n = 89, 62.2%) | NA | 143 | 52.3 ± 14.1 | PFS (HR) PLR (cut-off value: 201) Ua: 1.43 (0.87–2.35) Ma: 1.71 (0.80—3.66) NLR (cut-off value: 3.43) Ua: 2.11 (1.29–3.46) Ma: 2.20 (1.03–4.70) | OS (HR) PLR (cut-off value: 201) Ua: 1.76 (1.02–3.06) Ma: 2.05 (0.85–4.95) NLR (cut-off value: 3.43) Ua: 2.90 (1.66–5.05) Ma: 3.37 (1.39–8.15) | 8 | |
Asher/2011/UK [15] | OC; Serous papillary histology (n = 117, 49.6%); FIGO stage III-IV (n = 141, 60%) | Surgery followed by chemotherapy | 235 | 62 (24–90) | 24.5 (0.3–191.1) | NA | OS (HR) PLR (cut-off value: 300) Ua: 1.863 (1.37–2.534) Ma: 1.698 (1.031–2.797) NLR (cut-off value: 4) Ua: 1.686 (1.231–2.310) Ma: 0.865 (0.521–1.437) | 7 |
Williams/2014/USA [16] | OC; Serous papillary histology (n = 300, 58%); FIGO stage III-IV (n = 308, 61%) | NA | 519 | ≥55 ys: 56% | 68.4 (1-252) | NA | OS (HR) NLR (cut-off value: 3.6) Ua: 1.43 (1.13,1.81) Ma: 1.37 (1.06, 1.76) | 7 |
Thavaramara/2011/Thailand [17] | EOC; FIGO stage III-IV (n = 61, 47.6%) | Gynecologic surgery followed by chemotherapy | 129 | 49.6 ± 12.5 | NA | PFS (HR) NLR (cut-off value: 2.8) Ua: NA Ma: 0.7 (0.3-1.4) | OS (HR) NLR (cut-off value: 2.8) Ua: NA Ma: 0.7 (0.3-1.6) | 8 |
Raungkaewmanee/2014/ Thailand [11] | EOC; Serous papillary histology (n = 136, 81.9%); FIGO stage III-IV (n = 78, 47%) | Surgery followed by chemotherapy | 166 | 53 (23-85) | 28.3 (6.1-94.4) | PFS (HR) PLR (cut-off value: 200) Ua: 1.89 (1.24–2.88) Ma: 1.51 (0.88-2.61) PFS (HR) NLR (cut-off value: 2.6) Ua: 1.16 (0.91-1.49) Ma: NA | OS (HR) PLR (cut-off value: 200) Ua: 2.67 (1.43–4.98) Ma: 1.41 (0.77-2.56) OS (HR) NLR (cut-off value: 2.6) Ua: 1.19 (0.72-1.98) Ma: NA | 9 |
Feng/2016/ China [18] | HGSC; FIGO stage III-IV (n = 800, 91.4%) | Primary staging or debulking surgery, and 66.9% patients followed by chemotherapy | 875 | 56 (30–90) | 29 (1–115) | PFS (HR) NLR (cut-off value: 3.24) Ua: NA Ma: 1.250 (1.052–1.484) | OS (HR) NLR (cut-off value: 3.24) Ua: NA Ma: 1.189 (0.940–1.504) | 8 |
Zhang/2015/ China [19] | OC; FIGO stage III-IV (n = 137, 72.1%) | cytoreductive surgery followed by platinum-based chemotherapy | 190 | 51 (24–76) | 43 (2–164) | PFS (HR) PLR (cut-off value: 203) Ua: 2.224 (1.626–3.042) Ma: 1.852 (1.271–2.697) NLR (cut-off value: 3.4) Ua: 2.012 1.476–2.741 Ma: NA | OS (HR) PLR (cut-off value: 203) Ua: 2.490 (1.758–3.527) Ma: 2.158 (1.468–3.171) NLR (cut-off value: 3.4) Ua: 2.172 (1.545–3.054) Ma: NA | 9 |